Nicotinamide N-Methyl Transferase as a Predictive Marker of Tubular Fibrosis in CKD

References

• Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA. 2019;322(13):1294. doi:10.1001/jama.2019.14745
   PubMed Web of Science ®Google Scholar
• Rossing P, Caramori ML, Chan JCN, et al. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1–127.
   PubMed Web of Science ®Google Scholar
• Benjamin O, Lappin SL. End-Stage Renal Disease. In: StatPearls. StatPearls Publishing; 2021.
   Google Scholar
• Zsom L, Zsom M, Salim SA, Fülöp T. Estimated glomerular filtration rate in chronic kidney disease: a critical review of estimate-based predictions of individual outcomes in kidney disease. Toxins. 2022;2022:16.
   Google Scholar
• Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. Lancet. 2017;389(10075):1238–1252. doi:10.1016/S0140-6736(16)32064-5
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and Treatment of CKD. JASN. 2012;23(12):1917–1928. doi:10.1681/ASN.2012040390
   Web of Science ®Google Scholar
• Yan Z, Wang G, Shi X. Advances in the progression and prognosis biomarkers of chronic kidney disease. Front Pharmacol. 2021;12:785375. doi:10.3389/fphar.2021.785375
   PubMed Web of Science ®Google Scholar
• Ntrinias T, Papasotiriou M, Balta L, et al. Biomarkers in progressive chronic kidney disease. Still a long way to go. PRILOZI. 2019;40(3):27–39. doi:10.2478/prilozi-2020-0002
   PubMedGoogle Scholar
• Zhang WR, Parikh CR. Biomarkers of acute and chronic kidney disease. Annu Rev Physiol. 2019;81(1):309–333. doi:10.1146/annurev-physiol-020518-114605
   PubMedGoogle Scholar
• Ix JH, Shlipak MG. The promise of tubule biomarkers in kidney disease: a review. Am J Kidney Dis. 2021;78(5):719–727. doi:10.1053/j.ajkd.2021.03.026
   PubMed Web of Science ®Google Scholar
• Pissios P. Nicotinamide N -methyltransferase: more than a vitamin B3 clearance enzyme. Trend Endocrinol Metabol. 2017;28(5):340–353. doi:10.1016/j.tem.2017.02.004
   PubMed Web of Science ®Google Scholar
• Komatsu M, Kanda T, Urai H, et al. NNMT activation can contribute to the development of fatty liver disease by modulating the NAD + metabolism. Sci Rep. 2018;8(1):8637. doi:10.1038/s41598-018-26882-8
   PubMedGoogle Scholar
• Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258–262. doi:10.1038/nature13198
   PubMed Web of Science ®Google Scholar
• Song Q, Chen Y, Wang J, et al. ER stress-induced upregulation of NNMT contributes to alcohol-related fatty liver development. J Hepatol. 2020;73(4):783–793. doi:10.1016/j.jhep.2020.04.038
   PubMed Web of Science ®Google Scholar
• Ehebauer F, Ghavampour S, Kraus D. Glucose availability regulates nicotinamide N-methyltransferase expression in adipocytes. Life Sci. 2020;248:117474. doi:10.1016/j.lfs.2020.117474
   PubMed Web of Science ®Google Scholar
• Reustle A, Menig LS, Leuthold P, et al. Nicotinamide-N-methyltransferase is a promising metabolic drug target for primary and metastatic clear cell renal cell carcinoma. Clin Transl Med. 2022;12(6):e883. doi:10.1002/ctm2.883
   PubMed Web of Science ®Google Scholar
• Campagna R, Pozzi V, Spinelli G, et al. The Utility of Nicotinamide N-methyltransferase as a potential biomarker to predict the oncological outcomes for urological cancers: an update. Biomolecules. 2021;11(8):1214. doi:10.3390/biom11081214
   PubMed Web of Science ®Google Scholar
• Zhang W, Rong G, Gu J, et al. Nicotinamide N-methyltransferase ameliorates renal fibrosis by its metabolite 1-methylnicotinamide inhibiting the TGF-β1/Smad3 pathway. FASEB J. 2022;36(3):e22084. doi:10.1096/fj.202100913RRR
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kume S, Araki H, et al. 1-Methylnicotinamide ameliorates lipotoxicity-induced oxidative stress and cell death in kidney proximal tubular cells. Free Radic Biol Med. 2015;89:831–841. doi:10.1016/j.freeradbiomed.2015.10.414
   PubMed Web of Science ®Google Scholar
• Kim HC, Mofarrahi M, Vassilakopoulos T, et al. Expression and functional significance of nicotinamide N-methyl transferase in skeletal muscles of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(8):797–805. doi:10.1164/rccm.200906-0936OC
   PubMed Web of Science ®Google Scholar
• Takahashi R, Kanda T, Komatsu M, et al. The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease. Sci Rep. 2022;12(1):6398. doi:10.1038/s41598-022-10476-6
   PubMed Web of Science ®Google Scholar
• Nephroseq Login; 2022. Available from: https://www.nephroseq.org/resource/login.html. Accessed July 18, 2023.
   Google Scholar
• Rudnicki M, Perco P, D′haene B, et al. Renal microRNA- and RNA-profiles in progressive chronic kidney disease. Eur J Clin Invest. 2016;46(3):213–226. doi:10.1111/eci.12585
   PubMed Web of Science ®Google Scholar
• Wettenhall JM, Smyth GK. limmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics. 2004;20(18):3705–3706. doi:10.1093/bioinformatics/bth449
   PubMed Web of Science ®Google Scholar
• Levey AS, Inker LA, Coresh J. eGFREstimation: from Physiology to Public Health. Am J Kidney Dis. 2014;63(5):820–834. doi:10.1053/j.ajkd.2013.12.006
   PubMed Web of Science ®Google Scholar
• Lamb EJ, Levey AS, Stevens PE, et al. Kidney Disease Improving Global Outcomes (KDIGO) - Search Results. Clin Chem. 2013;59(3):462–465. doi:10.1373/clinchem.2012.184259
   PubMed Web of Science ®Google Scholar
• Cattran DC, Coppo R, Cook HT, et al.; A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534–545. doi:10.1038/ki.2009.243
   PubMed Web of Science ®Google Scholar
• Latt KZ, Heymann J, Jessee JH, et al. Urine Single-Cell RNA sequencing in focal segmental glomerulosclerosis reveals inflammatory signatures. Kidney Int Rep. 2022;7(2):289–304. doi:10.1016/j.ekir.2021.11.005
   PubMed Web of Science ®Google Scholar
• Noh MR, Woo CH, Park MJ, In Kim J, Park KM. Ablation of C/EBP homologous protein attenuates renal fibrosis after ureteral obstruction by reducing autophagy and microtubule disruption. Biochimica Et Biophysica Acta. 2018;1864(5):1634–1641. doi:10.1016/j.bbadis.2018.02.001
   Web of Science ®Google Scholar
• Kannt A, Rajagopal S, Kadnur SV, et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep. 2018;8(1):3660. doi:10.1038/s41598-018-22081-7
   PubMedGoogle Scholar
• Iyamu ID, Huang R. Mechanisms and inhibitors of nicotinamide N-methyltransferase. RSC Med Chem. 2021;12(8):1254–1261. doi:10.1039/D1MD00016K
   PubMedGoogle Scholar
• Dubin RF, Rhee EP. Proteomics and metabolomics in kidney disease, including insights into etiology, treatment, and prevention. CJASN. 2020;15(3):404–411. doi:10.2215/CJN.07420619
   PubMed Web of Science ®Google Scholar
• Gyurászová M, Gurecká R, Bábíčková J, Tóthová Ľ. Oxidative stress in the pathophysiology of kidney disease: implications for noninvasive monitoring and identification of biomarkers. Oxid Med Cell Longev. 2020;2020:5478708. doi:10.1155/2020/5478708
   PubMed Web of Science ®Google Scholar
• Rysz J, Gluba-Brzózka A, Franczyk B, Jabłonowski Z, Ciałkowska-Rysz A. Novel biomarkers in the diagnosis of chronic kidney disease and the prediction of its outcome. IJMS. 2017;18(8):1702. doi:10.3390/ijms18081702
   Google Scholar
• Cummins TD, Powell DW, Wilkey DW, et al. Quantitative mass spectrometry normalization in urine biomarker analysis in nephrotic syndrome. Glomerular Dis. 2022;2(3):121–131. doi:10.1159/000522217
   PubMedGoogle Scholar
• Priyadarshini G, Rajappa M. Predictive markers in chronic kidney disease. Clin Chim Acta. 2022;535:180–186. doi:10.1016/j.cca.2022.08.018
   PubMed Web of Science ®Google Scholar
• Yamanouchi M, Furuichi K, Hoshino J, et al. Nonproteinuric versus proteinuric phenotypes in diabetic kidney disease: a propensity score–matched analysis of a nationwide, biopsy-based cohort study. Diabetes Care. 2019;42(5):891–902. doi:10.2337/dc18-1320
   PubMed Web of Science ®Google Scholar
• Koye DN, Magliano DJ, Reid CM, et al. Risk of Progression of Nonalbuminuric CKD to end-stage kidney disease in people with diabetes: the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2018;72(5):653–661. doi:10.1053/j.ajkd.2018.02.364
   PubMed Web of Science ®Google Scholar
• Gomes MF, Mardones C, Xipell M, et al. The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis. J Nephrol. 2021;34(6):1897–1905. doi:10.1007/s40620-021-01007-z
   PubMed Web of Science ®Google Scholar
• Feldreich T, Nowak C, Carlsson AC, et al. The association between plasma proteomics and incident cardiovascular disease identifies MMP-12 as a promising cardiovascular risk marker in patients with chronic kidney disease. Atherosclerosis. 2020;307:11–15. doi:10.1016/j.atherosclerosis.2020.06.013
   PubMed Web of Science ®Google Scholar
• Zhang J, You XX, wen YS, Wang J, He C. Nicotinamide N-methyltransferase protein expression in renal cell cancer. J Zhejiang Univ Sci B. 2010;11(2):136–143. doi:10.1631/jzus.B0900249
   PubMed Web of Science ®Google Scholar
• Sartini D, Muzzonigro G, Milanese G, et al. Upregulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: potential for the development of a urine-based diagnostic test. Cell Biochem Biophys. 2013;65(3):473–483. doi:10.1007/s12013-012-9451-1
   PubMed Web of Science ®Google Scholar
• Pozzi V, Di Ruscio G, Sartini D, et al. Clinical performance and utility of a NNMT-based urine test for bladder cancer. Int J Biol Markers. 2018;33(1):94–101. doi:10.5301/ijbm.5000311
   PubMed Web of Science ®Google Scholar
• Tang SW, Yang TC, Lin WC, et al. Nicotinamide N-methyltransferase induces cellular invasion through activating matrix metalloproteinase-2 expression in clear cell renal cell carcinoma cells. Carcinogenesis. 2011;32(2):138–145. doi:10.1093/carcin/bgq225
   PubMed Web of Science ®Google Scholar
• Critselis E, Lambers Heerspink H. Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression. Nephrol Dial Transplant. 2015;gfv062. doi:10.1093/ndt/gfv062
   Web of Science ®Google Scholar
• Pontillo C, Jacobs L, Staessen JA, et al. A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrol Dial Transplant. 2016:gfw239. doi:10.1093/ndt/gfw239
   Google Scholar
• Zhang SF, Mao XJ, Jiang WM, Fang ZY. Granule protects against hypertension-induced renal injury by epigenetic mechanism linked to Nicotinamide N-Methyltransferase (NNMT) expression. J Ethnopharmacol. 2020;255:112738. doi:10.1016/j.jep.2020.112738
   PubMed Web of Science ®Google Scholar